<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: Some <z:hpo ids='HP_0001297'>strokes</z:hpo> of unknown etiology may be the result of a <z:e sem="disease" ids="C0238096" disease_type="Disease or Syndrome" abbrv="">paradoxical embolism</z:e> traversing through a nonfused foramen ovale (<z:hpo ids='HP_0001655'>patent foramen ovale</z:hpo> [<z:mp ids='MP_0004225'>PFO</z:mp>]) </plain></SENT>
<SENT sid="1" pm="."><plain>The utility of percutaneously placed devices for treatment of patients with cryptogenic <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo> (<z:hpo ids='HP_0002326'>TIA</z:hpo>) and <z:mp ids='MP_0004225'>PFO</z:mp> is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, there are no clear data about the utility of medical interventions or other surgical procedures in this situation </plain></SENT>
<SENT sid="3" pm="."><plain>Despite limited data, many patients are being treated with <z:mp ids='MP_0004225'>PFO</z:mp> closure devices </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, there is a strong need for clinical trials that test the potential efficacy of <z:mp ids='MP_0004225'>PFO</z:mp> occlusive devices in this situation </plain></SENT>
<SENT sid="5" pm="."><plain>To address this gap in medical knowledge, we designed the CLOSURE I trial, a randomized, clinical trial comparing the use of a percutaneously placed <z:mp ids='MP_0004225'>PFO</z:mp> occlusive device and best medical therapy versus best medical therapy alone for prevention of recurrent ischemic neurologic symptoms among persons with <z:hpo ids='HP_0002326'>TIA</z:hpo> or <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>STUDY DESIGN: This prospective, multicenter, randomized, controlled trial has finished enrollment </plain></SENT>
<SENT sid="7" pm="."><plain>Two-year follow-up for <z:hpo ids='HP_0000001'>all</z:hpo> 910 patients is required </plain></SENT>
<SENT sid="8" pm="."><plain>The primary end point is the 2-year incidence of <z:hpo ids='HP_0001297'>stroke</z:hpo> or <z:hpo ids='HP_0002326'>TIA</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality for the first 30 days, and neurologic mortality from â‰¥ 31 days of follow-up, as adjudicated by a panel of physicians who are unaware of treatment allocation </plain></SENT>
<SENT sid="9" pm="."><plain>This article describes the rationale and study design of CLOSURE I </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: This trial should provide information as to whether the STARFlex septal closure system is safe and more effective than best medical therapy alone in preventing recurrent <z:hpo ids='HP_0001297'>stroke</z:hpo>/<z:hpo ids='HP_0002326'>TIA</z:hpo> and mortality in patients with <z:mp ids='MP_0004225'>PFO</z:mp> and whether the STARFlex septal closure device can demonstrate superiority compared with best medical therapy alone </plain></SENT>
<SENT sid="11" pm="."><plain>Clinical Trial Registration-URL: http://www.clinicaltrials.gov </plain></SENT>
<SENT sid="12" pm="."><plain>Unique identifier: NCT00201461 </plain></SENT>
</text></document>